Corbus Pharmaceuticals Statistics
Corbus Pharmaceuticals (3371) Stock Statistics & Valuation Metrics
Total Valuation
Corbus Pharmaceuticals has a market cap or net worth of EUR 56.54M. The enterprise value is EUR 30.69M.
- Market Cap
- EUR 56.54M
- Enterprise Value
- EUR 30.69M
Share Statistics
Corbus Pharmaceuticals has 20,606,760 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 20,606,760
- Owned by Insiders
- 12.09%
- Owned by Institutions
- 79.30%
Financial Efficiency
Corbus Pharmaceuticals’s return on equity (ROE) is -0.53 and return on invested capital (ROIC) is -57.20%.
- Return on Equity (ROE)
- -0.53
- Return on Assets (ROA)
- -0.47
- Return on Invested Capital (ROIC)
- -57.20%
- Return on Capital Employed (ROCE)
- -0.58
- Revenue Per Employee
- 0
- Profits Per Employee
- -2.18M
- Employee Count
- 36
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Corbus Pharmaceuticals is -0.43. Corbus Pharmaceuticals’s PEG ratio is 0.03.
- PE Ratio
- -0.43
- PS Ratio
- 0.00
- PB Ratio
- 0.67
- Price to FCF
- -0.61
- Price to Operating Cash Flow
- -0.62
- PEG Ratio
- 0.03
Income Statement
In the last 12 months, Corbus Pharmaceuticals had revenue of 0 and earned -78.54M in profits. Earnings per share was -5.90.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -85.31M
- Pretax Income
- -78.54M
- Net Income
- -78.54M
- EBITDA
- -78.30M
- Earnings Per Share (EPS)
- -5.90
Cash Flow
In the last 12 months, operating cash flow was -92.36M and capital expenditures -34,000, giving a free cash flow of -92.39M billion.
- Operating Cash Flow
- -92.36M
- Free Cash Flow
- -92.39M
- Free Cash Flow per Share
- -4.43
Dividends & Yields
Corbus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -163.33%
- Earnings Yield
- -203.35%
Stock Price Statistics
- Beta
- 0.95
- 52-Week Price Change
- -68.53%
- 50-Day Moving Average
- 4.76
- 200-Day Moving Average
- 7.02
- Relative Strength Index (RSI)
- 37.56
- Average Volume (3m)
- 233
Important Dates
Corbus Pharmaceuticals upcoming earnings date is Mar 15, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Mar 15, 2027
- Ex-Dividend Date
- ―
Financial Position
Corbus Pharmaceuticals as a current ratio of 8.07, with Debt / Equity ratio of 1.11%
- Current Ratio
- 8.07
- Quick Ratio
- 8.07
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.34
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Corbus Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Corbus Pharmaceuticals EV to EBITDA ratio is -0.26, with an EV/FCF ratio of -0.33.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.26
- EV to Free Cash Flow
- -0.33
- EV to Operating Cash Flow
- -0.33
Balance Sheet
Corbus Pharmaceuticals has EUR 115.34M in cash and marketable securities with EUR 3.91M in debt, giving a net cash position of EUR 111.43M billion.
- Cash & Marketable Securities
- EUR 115.34M
- Total Debt
- EUR 3.91M
- Net Cash
- EUR 111.43M
- Net Cash Per Share
- EUR 5.41
- Tangible Book Value Per Share
- EUR 4.07
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Corbus Pharmaceuticals is EUR 28.92, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 28.92
- Price Target Upside
- 950.24% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -6.00%
Scores
- Smart Score
- 7
- AI Score
- ―

